Related references
Note: Only part of the references are listed.Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice
Alexandre Roux et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Temozolomide during radiotherapy of glioblastoma multiforme Daily administration improves survival
Silke Birgit Nachbichler et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2017)
The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy
Christopher P. Millward et al.
ACTA NEUROCHIRURGICA (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy
Hailong Li et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2016)
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review
Lynn S. Ashby et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2016)
Association of the Extent of Resection With Survival in Glioblastoma A Systematic Review and Meta-analysis
Timothy J. Brown et al.
JAMA ONCOLOGY (2016)
Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas
Vladislav Pavlov et al.
BRITISH JOURNAL OF NEUROSURGERY (2015)
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
Manfred Westphal et al.
EUROPEAN JOURNAL OF CANCER (2015)
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel
Rachel Grossman et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial
Stuart H. Burri et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
Sajeel A. Chowdhary et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort
Johan Pallud et al.
NEURO-ONCOLOGY (2015)
MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma
Zheng Wang et al.
BIOMEDICAL REPORTS (2015)
Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma
Matthias Preusser et al.
CLINICAL NEUROPATHOLOGY (2014)
MGMT promoter methylation in plasma of glioma patients receiving temozolomide
Valentina Fiano et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma
Matthew M. Grabowski et al.
JOURNAL OF NEUROSURGERY (2014)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma
Jennifer L. Clarke et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial
Colin Watts et al.
ACTA NEUROCHIRURGICA (2013)
Implanted Carmustine Wafers Followed by Concomitant Radiochemotherapy to Treat Newly Diagnosed Malignant Gliomas: Prospective, Observational, Multicenter Study on 92 Cases
Julien Duntze et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma
Pasquale De Bonis et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2013)
The role of Gliadel wafers in the treatment of high-grade gliomas
Amade Bregy et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience
A. Gutenberg et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results Clinical article
Andrea Salmaggi et al.
JOURNAL OF NEUROSURGERY (2013)
The effects of the NICE Technology Appraisal 121 (Gliadel and Temozolomide) on survival in high-grade glioma
James Geoffrey Barr et al.
BRITISH JOURNAL OF NEUROSURGERY (2012)
O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide
Emmanuele Lechapt-Zalcman et al.
CANCER (2012)
Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: Efficacy and toxicity
Petra Miglierini et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2012)
RETROSPECTIVE COMPARISON OF CHEMORADIOTHERAPY FOLLOWED BY ADJUVANT CHEMOTHERAPY, WITH OR WITHOUT PRIOR GLIADEL IMPLANTATION (CARMUSTINE) AFTER INITIAL SURGERY IN PATIENTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMAS
Georges Noel et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas
T. A. Juratli et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients Clinical article
Tamara Ius et al.
JOURNAL OF NEUROSURGERY (2012)
Radiographic patterns of relapse in glioblastoma
Marc C. Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2011)
The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival
Kaisorn L. Chaichana et al.
NEUROLOGICAL RESEARCH (2011)
Extent of resection influences outcomes for patients with gliomas
N. Sanai et al.
REVUE NEUROLOGIQUE (2011)
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience
Hans Christoph Bock et al.
NEUROSURGICAL REVIEW (2010)
Overall Survival of Newly Diagnosed Glioblastoma Patients Receiving Carmustine Wafers Followed by Radiation and Concurrent Temozolomide Plus Rotational Multiagent Chemotherapy
Mary Lou Affronti et al.
CANCER (2009)
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme
Matthew J. McGirt et al.
JOURNAL OF NEUROSURGERY (2009)
Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: A 10-year institutional experience
Frank J. Attenello et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
Justin S. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients
Edward Pan et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Methylated tumor-specific DNA as a plasma biomarker in patients with glioma
KD Weaver et al.
CANCER INVESTIGATION (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
M Lacroix et al.
JOURNAL OF NEUROSURGERY (2001)
Share Paper
